Drugs interactions for Dupixent®

  • 11 Major drug interactions (including ingredients like Adenovirus type 7 vaccine live, Anthrax vaccine, Bacillus calmette-guerin substrain tice live antigen)
  • 1 Moderate drug interactions (including ingredients like Pozelimab)
  • 159 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
171 interactions for Dupixent®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Dupixent®.
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Dupilumab.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Dupilumab.
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Dupilumab.
Chikungunya vaccine (live, attenuated)
The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Dupilumab.
Human adenovirus e serotype 4 strain cl-68578 antigen
The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Dupilumab.
Rubella virus vaccine
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Dupilumab.
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Dupilumab.
Typhoid Vaccine Live
The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Dupilumab.
Varicella zoster vaccine (live/attenuated)
The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Dupilumab.
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dupilumab.
Yellow fever vaccine
The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Dupilumab.
Pozelimab
The serum concentration of Pozelimab can be decreased when it is combined with Dupilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Dupilumab.
Aducanumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Aducanumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dupilumab.
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Dupilumab.
Amivantamab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Amivantamab.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Dupilumab.
Ansuvimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Ansuvimab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Dupilumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Dupilumab.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dupilumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Dupilumab.
Atezolizumab
The risk or severity of adverse effects can be increased when Atezolizumab is combined with Dupilumab.
Atoltivimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Atoltivimab.
Avelumab
The risk or severity of adverse effects can be increased when Avelumab is combined with Dupilumab.
Axatilimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Axatilimab.
Bamlanivimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Bamlanivimab.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Dupilumab.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Dupilumab.
Benralizumab
The risk or severity of adverse effects can be increased when Benralizumab is combined with Dupilumab.
Bevacizumab
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.
Bezlotoxumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Bezlotoxumab.
Bimekizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Bimekizumab.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Dupilumab.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dupilumab.
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Dupilumab.
Brolucizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Brolucizumab.
Burosumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Burosumab.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Dupilumab.
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dupilumab.
Cemiplimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Cemiplimab.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Dupilumab.
Cetuximab
The risk or severity of adverse effects can be increased when Cetuximab is combined with Dupilumab.
Cilgavimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Cilgavimab.
Clesrovimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Clesrovimab.
Conjugated estrogens
Conjugated estrogens may increase the thrombogenic activities of Dupilumab.
Cosibelimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Cosibelimab.
Crovalimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Crovalimab.
Daratumumab
The risk or severity of adverse effects can be increased when Daratumumab is combined with Dupilumab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Dupilumab.
Digoxin Immune Fab (Ovine)
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dupilumab.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Dupilumab.
Donanemab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Donanemab.
Dostarlimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Dostarlimab.
Dulaglutide
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Dupilumab.
Durvalumab
The risk or severity of adverse effects can be increased when Durvalumab is combined with Dupilumab.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dupilumab.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Dupilumab.
Eflapegrastim
The risk or severity of adverse effects can be increased when Dupilumab is combined with Eflapegrastim.
Eftrenonacog alfa
The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Dupilumab.
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Dupilumab.
Emapalumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Emapalumab.
Emicizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Emicizumab.
Eptinezumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Eptinezumab.
Erenumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Erenumab.
Esterified estrogens
Esterified estrogens may increase the thrombogenic activities of Dupilumab.
Estetrol
Estetrol may increase the thrombogenic activities of Dupilumab.
Estradiol
Estradiol may increase the thrombogenic activities of Dupilumab.
Estradiol acetate
Estradiol acetate may increase the thrombogenic activities of Dupilumab.
Estradiol cypionate
Estradiol cypionate may increase the thrombogenic activities of Dupilumab.
Estradiol valerate
Estradiol valerate may increase the thrombogenic activities of Dupilumab.
Estriol
Estriol may increase the thrombogenic activities of Dupilumab.
Estrone sulfate
Estrone sulfate may increase the thrombogenic activities of Dupilumab.
Ethinylestradiol
Ethinylestradiol may increase the thrombogenic activities of Dupilumab.
Evolocumab
The risk or severity of adverse effects can be increased when Evolocumab is combined with Dupilumab.
Fanolesomab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Fanolesomab.
Fremanezumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Fremanezumab.
Galcanezumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Galcanezumab.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab.
Glofitamab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Glofitamab.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Dupilumab.
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Dupilumab.
Hepatitis B immune globulin
The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Dupilumab.
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Dupilumab is combined with Human cytomegalovirus immune globulin.
Human immunoglobulin G
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dupilumab.
Human Rho(D) immune globulin
The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Dupilumab.
Human varicella-zoster immune globulin
The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Dupilumab.
Ibalizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Ibalizumab.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab.
Idarucizumab
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Dupilumab.
Inebilizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Inebilizumab.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Dupilumab.
Inotuzumab ozogamicin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dupilumab.
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dupilumab.
Isatuximab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Isatuximab.
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Dupilumab.
Lanadelumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Lanadelumab.
Lebrikizumab
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Dupilumab.
Lecanemab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Lecanemab.
Linvoseltamab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Linvoseltamab.
Loncastuximab tesirine
The risk or severity of adverse effects can be increased when Dupilumab is combined with Loncastuximab tesirine.
Maftivimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Maftivimab.
Margetuximab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Margetuximab.
Marstacimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Marstacimab.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Dupilumab.
Mirvetuximab soravtansine
The risk or severity of adverse effects can be increased when Dupilumab is combined with Mirvetuximab Soravtansine.
Mogamulizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Mogamulizumab.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Mosunetuzumab.
Natalizumab
The risk or severity of adverse effects can be increased when Natalizumab is combined with Dupilumab.
Necitumumab
The risk or severity of adverse effects can be increased when Necitumumab is combined with Dupilumab.
Nemolizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Nemolizumab.
Nipocalimab
The serum concentration of Dupilumab can be decreased when it is combined with Nipocalimab.
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Dupilumab.
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dupilumab.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dupilumab.
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Dupilumab.
Odesivimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Odesivimab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Dupilumab.
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Dupilumab.
Omalizumab
The risk or severity of adverse effects can be increased when Omalizumab is combined with Dupilumab.
Palivizumab
The risk or severity of adverse effects can be increased when Palivizumab is combined with Dupilumab.
Panitumumab
The risk or severity of adverse effects can be increased when Panitumumab is combined with Dupilumab.
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Dupilumab.
Penpulimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Penpulimab.
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Dupilumab.
Polatuzumab vedotin
The risk or severity of adverse effects can be increased when Dupilumab is combined with Polatuzumab vedotin.
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dupilumab.
Ranibizumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dupilumab.
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Dupilumab.
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Dupilumab.
Relatlimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Relatlimab.
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Dupilumab.
Risankizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Dupilumab.
Romosozumab
The risk or severity of adverse effects can be increased when Romosozumab is combined with Dupilumab.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Rozanolixizumab.
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Dupilumab is combined with Sacituzumab govitecan.
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Dupilumab.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Dupilumab.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Dupilumab.
Sotatercept
The risk or severity of adverse effects can be increased when Sotatercept is combined with Dupilumab.
Sotrovimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Sotrovimab.
Spesolimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Spesolimab.
Sutimlimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Sutimlimab.
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dupilumab.
Synthetic Conjugated Estrogens, B
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dupilumab.
Tafasitamab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tafasitamab.
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Dupilumab is combined with Telisotuzumab vedotin.
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Dupilumab.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Dupilumab.
Tetanus immune globulin, human
The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Dupilumab.
Tezepelumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tezepelumab.
Tildrakizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tildrakizumab.
Tislelizumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tislelizumab.
Tisotumab vedotin
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tisotumab vedotin.
Tixagevimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tixagevimab.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Dupilumab.
Toripalimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Toripalimab.
Tralokinumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Tralokinumab.
Trastuzumab
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dupilumab.
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Dupilumab is combined with Trastuzumab deruxtecan.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dupilumab.
Tremelimumab
The risk or severity of adverse effects can be increased when Tremelimumab is combined with Dupilumab.
Ublituximab
The risk or severity of adverse effects can be increased when Ublituximab is combined with Dupilumab.
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dupilumab.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Dupilumab.
Vilobelimab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Vilobelimab.
Zanidatamab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Zanidatamab.
Zenocutuzumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Zenocutuzumab.
Zolbetuximab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Zolbetuximab.